NEW YORK, May 21 (Reuters) - Bristol-Myers Squibb Co.'s schizophrenia drug Abilify proved effective as an add-on therapy for patients suffering from major depression who were not getting satisfactory ...

Adding another antidepressant to the mix was more helpful than switching agents in older adults with treatment-resistant depression, a two-step, open-label trial suggested. In the first step of the ...

For older adults with clinical depression that has not responded to standard treatments, adding the drug aripiprazole (brand name Abilify) to an antidepressant they're already taking is more effective ...

Abilify (aripiprazole) is a brand-name drug that’s prescribed for certain mental health conditions, including schizophrenia and depression. Abilify has interactions with some other drugs, foods, and ...

A psychiatric medication system in the form of a pill with a built-in digital tracking device gained approval from the US Food and Drug Administration on Monday. Abilify MyCite, a form of aripiprazole ...